Skip to content

Search

Assessing the protective effect of influenza vaccine against laboratory confirmed influenza in hospitalised children aged 6-59 months

Influenza vaccine was offered to all children aged 6-59 months resident in Western Australia in 2008, and we wished to evaluate the effectiveness of this immunisation programme.

Method of bacterial killing differentially affects the human innate immune response to Staphylococcus epidermidis

In vitro investigations of human innate immune responses to extracellular bacteria commonly utilise killed preparations in preference to live organisms

Th2-polarisation of cellular immune memory to neonatal pertussis vaccination

Current infant vaccination against pertussis in North America and Australia requires three doses of vaccines including diphtheria, tetanus and acellular...

TLR2 mediates recognition of live staphylococus epidermidis

Staphylococcus epidermidis is a nosocomial pathogen that causes catheter-associated bacteremia in the immunocompromised, including those at the extremes of age

Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers Aged 18-36 months

A bivalent, recombinant, factor H-binding protein (rLP2086) vaccine was developed to protect against invasive Neisseria meningitidis serogroup B (MnB) in...

Can linked emergency department data help assess the out-of-hospital burden of acute lower respiratory infections

There is a lack of data on the out-of-hospital burden of acute lower respiratory infections (ALRI) in developed countries.

A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults:

Neisseria meningitidis is a leading cause of meningitis and septicaemia, but a broadly-protective vaccine against endemic serogroup B disease is not licensed...

International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.

The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A...

Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children

Our study will be the first to assess vaccine efficacy targeting H. influenzae in children with recurrent PBB, CSLD and bronchiectasis.